학술논문

Protective immunity in recurrent Staphylococcus aureus infection reflects localized immune signatures and macrophage-conferred memory.
Document Type
article
Source
Proceedings of the National Academy of Sciences of USA. 115(47)
Subject
Staphylococcus aureus
adoptive transfer
innate immune memory
macrophage
recurrent skin infection
Adoptive Transfer
Animals
Chemokine CCL5
Chemokine CXCL10
Dendritic Cells
Disease Models
Animal
Homeodomain Proteins
Immunity
Innate
Immunologic Memory
Interferon-gamma
Interleukin-17
Interleukin-6
Macrophages
Male
Methicillin-Resistant Staphylococcus aureus
Mice
Mice
Inbred C57BL
Mice
Knockout
Staphylococcal Skin Infections
Th17 Cells
Language
Abstract
Staphylococcus aureus is the leading cause of skin and skin structure infection (SSSI), a primary portal of entry for invasive infection. Our prior studies discovered a role for protective innate memory against recurrent methicillin-resistant S. aureus (MRSA) SSSI. In the present study, the dynamics and mechanisms of this response were explored in recurrent SSSI in WT mice. Priming by prior infection reduced skin lesion severity and MRSA burden, and protected against dissemination at day 7 but not day 2. Cytokine and cellular signatures in SSSI differed at day 2 versus 7, and were distinct in skin versus blood or spleen. Cytokines associated with protection in skin included increased IL-17, IL-6, monokine inducible by IFN-γ (MIG), and RANTES, while increased IP-10 correlated with protection from dissemination. Cellular signatures of protection included increased Th17, M1 macrophage, and dendritic cell populations in abscesses, and total macrophages in lymph nodes. Priming potentiated S. aureus-specific phagocytic killing by bone marrow-derived macrophages in vitro, and their adoptive transfer into naïve skin afforded protective efficacy in vivo. Present findings indicate that protective immunity in recurrent S. aureus infection is locally targeted, and involves specific memory conferred by macrophages. These insights provide targets for vaccine and immunotherapeutic development against MRSA.